Effect of mycobacterium on clinical and laboratory parameters in COVID-19


  • Vitrag Shah Department of critical care medicine, Velocity Hospital, Surat, Gujarat, India
  • Pratik Patel Department of medical affairs, Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India
  • Ameet Soni Department of medical affairs, Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India




COVID-19, CRP, D-dimer, Mycobacterium w, RT-PCR


Background: Initial wave of COVID-19 created a massive health crisis everywhere including India due to a limited understanding of the disease pathology. Most physicians used sepsis as a prototype to manage COVID-19, as there are similarities. Heat-killed Mycobacterium w (Mw) (inj. sepsivac®) is a known immunomodulator approved for the treatment of gram-negative sepsis. Our purpose of this observation is to evaluate the safety and efficacy of Inj sepsivac in COVID-19 patients along with the standard of care.

Methods: Total 49 patients data with reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed critically ill COVID-19 patients who were admitted at Velocity Hospital, Surat between May 4, 2021, and May 18, 2021 were evaluated. They were evaluated for vital parameters like pulse, blood pressure, respiratory rate and temperature as well as laboratory parameters like ALT, S IL-6, serum creatinine and CRP during three follow-up visits after the administration of Inj sepsivac. Further follow-up was done until the discharge/death of the patient.

Results: There was a statistically significant reduction of mean CRP observed compared to the baseline value during all follow-up visits. The rest of the laboratory parameters as well as clinical assessment did not show any significant change as compared to baseline. Out of 49, two patients died (mortality rate; 4%). Inj. sepsivac was found to be well tolerated without any systemic side effects.

Conclusions: The addition of Mw to the standard of care can improve laboratory parameters like CRP, without any safety concerns. These results should be further substantiated by larger randomised clinical trials.


Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489-93.

Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. DARU J Pharmaceut Sci. 2020;1-7.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.

Remy KE, Brakenridge SC, Francois B, Daix T, Deutschman CS, Monneret G, et al. Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Resp Med. 2020;8(10):946-9.

Sepsivac [package insert]. Ahmedabad, India: Cadila Pharmaceuticals Limited; 2019.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625-38.

Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39:517-28.

Desai NM, Khamar BM. Immunotherapy for tuberculous pericarditis. N Engl J Med. 2014;371(26):2531-5.

Power CA, Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun. 1998;66(12):5743-50.

Kumar P, Tyagi R, Das G, Bhaskar S. Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in Toll-like receptor-dependent manner. Immunol. 2014;143(5):258-68.

Campana P, Parisi V, Leosco D, Bencivenga D, Della Ragione F, Borriello A. Dendritic cells and SARS-CoV-2 infection: still an unclarified connection. Cells. 2020;9(9):2046.

Kumar P, John V, Marathe S, Das G, Bhaskar S. Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner. J Leukoc Biol. 2015;97(3):511-20.

Sehgal IS, Bhalla A, Puri GD, Yaddanapudi LN, Singh M, Malhotra P, et al. Safety of an immunomodulator Mycobacterium w in COVID-19. Lung India. 2020;37(3):279-81.

Ingale A, Ingale F, Kunwar B, Ahmed S, Salvi K, Chavan V, et al. Role of Mycobacterium w for the treatment of COVID-19: an observational study. J Assoc Physicians India. 2021;69(1):19-22.




How to Cite

Shah, V., Patel, P., & Soni, A. (2023). Effect of mycobacterium on clinical and laboratory parameters in COVID-19. International Journal of Research in Medical Sciences, 11(10), 3710–3713. https://doi.org/10.18203/2320-6012.ijrms20233024



Original Research Articles